Frequently asked questions (FAQs)

NOT ACTUAL PATIENT

SAJAZIR™ (icatibant) Injection

SAJAZIR is an FDA-approved icatibant injection indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.1,2

HAE-nl-C1INH, formerly known as Type III, is a subcategory of HAE that is characterized by patients having functional C1-INH, but share the same subcutaneous and submucosal swelling of HAE attacks caused by bradykinin overproduction.3

SAJAZIR is a treatment option for HAE-nl-C1INH, while C1-inhibitor concentrate therapies are not always effective.4 SAJAZIR is a bradykinin B2-receptor antagonist indicated for the treatment of acute attacks of HAE.1

You can print and send an enrollment form to Cycle Vita at hello@cyclevita.life or fax it to them at 888-385-8482.

Download enrollment form

Patient support

Cycle Vita is our dedicated patient support program, which delivers product support* at every step.

Find out more

As soon as Cycle Vita receives a completed enrollment form, we can provide individualized support to eligible* patients, such as access to treatment, financial and pharmacy support, as well as clinical education and 1-to-1 self-administration training. We will reach out to you and your patient to take the next steps.

Find out more

A free supply of SAJAZIR is available to your eligible* patients while Cycle Vita secures appropriate Benefit Verification and assists with Prior Authorization. The Bridge Program may also be requested for existing patients who are temporarily experiencing disruption in therapy due to insurance coverage.

Find out more

Commercially insured eligible* patients who have been prescribed SAJAZIR may pay as little as $0 in co-pay. To find out more about eligibility criteria please contact Cycle Vita at 888-360-8482.

Find out more

Getting started

Complete a SAJAZIR enrollment form and either email it to our Cycle Vita team at hello@cyclevita.life or fax it to them at 888-385-8482.

Once they receive the form, our expert team will take care of all the details so your patients can get started on their treatment as soon as possible.

Please use the enrollment form rather than your own prescription form to avoid delays. You can use the Rx Checklist to help you complete the enrollment form correctly. And remember to specify dispense as written (DAW) on every enrollment form to ensure that your patients receive SAJAZIR and the support available through Cycle Vita.

Rx Checklist
A friendly, familiar team is waiting here at Cycle Vita, for you and your patients, at every step.
Cycle Vita Logo With Strapline
Cycle Vita Logo With Strapline
A friendly, familiar team is waiting here at Cycle Vita, for you, at every step.

+1 (888) 360-8482


*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.

References

  1. SAJAZIR™ (icatibant) Injection. Prescribing Information. Cycle Pharmaceuticals Limited.
  2. FDA. FDA-Approved Drugs. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212446 [Accessed: September 18 2024].​
  3. Sinnathamby ES, et al. 2023. Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology. Adv Ther. 2023;40(3):814-827. doi:10.1007/s12325-022-02401-0
  4. McKibbin L, Barber C, Kalicinsky C, Warrington R. 2019. Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol. 2019;15:66. doi:10.1186/s13223-019-0381-y.